yf_tkr_GSK · 2026-10-23 · Bullish AI sentiment
GSK (LSE:GSK) agreed an exclusive global licence with HUTCHMED for KRAS-EGFR antibody drug conjugate HMPL-A830, excluding China. The arrangement grants GSK rights to develop and commercialise HMPL-A830 worldwide outside mainland China, Hong Kong, Macau and Taiwan. HMPL-A830 is described as a first-in-class KRAS-EGFR targeted therapy for solid tumours including colorectal and pancreatic cancer. There is more to GSK than this HMPL-A830 KRAS-EGFR licensing deal with HUTCHMED alone. Our analysis...
Sector coverage: Healthcare · Drug Manufacturers - General
Read the original at yf_tkr_GSK ↗
Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.
Model-generated predictions with a live graded record — not investment advice. 模型生成的预测，非投资建议。